A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Ixekizumab (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT-P1
- Sponsors Eli Lilly
- 17 Oct 2017 Trial has been completed in Belgium (end date: 22 Sep 2017).
- 08 Oct 2017 Trial has been completed in Estonia and Bulgaria (End date: 2017-09-22).
- 05 Oct 2017 Trial has been completed in Estonia and Spain (End date: 2017-09-22).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History